BOSTON SCIENTIFIC CORP — Director's Dealing 2019

Mar 4, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2019-03-01

Reporting Person: Ballinger Kevin J. (EVP & Pres, Interven Cardio)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-01	Common Stock	S	20900.0000	$40.7441	Disposed	77572.0000	Direct
2019-03-03	Common Stock	M	3302.0000	$0.0000	Acquired	80874.0000	Direct
2019-03-03	Common Stock	F	1506.0000	$40.7500	Disposed	79368.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-03	Deferred Stock Units	$	M	3302.0000	Disposed	2022-03-03	Common Stock (3302.0000)	Direct

Footnotes

F1: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.74 to $40.76, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

F4: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F5: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant.